Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti PD-1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02446860
What this trial is testing

Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)

Who this might be right for
Renal Cell Carcinoma
Royal Marsden NHS Foundation Trust 15
Not applicableNot Yet RecruitingNCT05660213
What this trial is testing

Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer

Who this might be right for
Unresectable Hepatocellular Carcinoma
Fudan University 750
Testing effectiveness (Phase 2)Ended earlyNCT03178123
What this trial is testing

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Who this might be right for
Mucosal Melanoma
Shanghai Junshi Bioscience Co., Ltd. 6
Testing effectiveness (Phase 2)Ended earlyNCT01313416
What this trial is testing

Gemcitabine and CT-011 for Resected Pancreatic Cancer

Who this might be right for
Pancreatic NeoplasmsCancer of the PancreasNeoplasms Pancreatic+2 more
Augusta University 2
Testing effectiveness (Phase 2)UnknownNCT05282433
What this trial is testing

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
Zhongnan Hospital 45
Testing effectiveness (Phase 2)Ended earlyNCT04688658
What this trial is testing

Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Who this might be right for
Unresectable Melanoma
John Kirkwood 13
Early research (Phase 1)Active Not RecruitingNCT04606316
What this trial is testing

Surgical Nivolumab And Ipilimumab For Recurrent GBM

Who this might be right for
GlioblastomaGBMGlioblastoma Multiforme+1 more
Patrick Wen, MD 63
Testing effectiveness (Phase 2)Looking for participantsNCT05310643
What this trial is testing

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

Who this might be right for
Metastatic Colorectal Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group 30
Early research (Phase 1)Study completedNCT03326752
What this trial is testing

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Who this might be right for
Advanced Non Small Cell Lung Cancer
Dynavax Technologies Corporation 26
Testing effectiveness (Phase 2)Study completedNCT06076135
What this trial is testing

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRadiotherapyImmune Checkpoint Blockade+1 more
Chuangzhen Chen 24
Early research (Phase 1)UnknownNCT05222009
What this trial is testing

G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Granulocyte Colony-Stimulating FactorPD-1 Inhibitor
Sun Yat-sen University 25
Testing effectiveness (Phase 2)UnknownNCT05684211
What this trial is testing

Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd. 84
Testing effectiveness (Phase 2)Ended earlyNCT03904108
What this trial is testing

Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
ROGER S KERESZTES MD 3
Large-scale testing (Phase 3)Not Yet RecruitingNCT06957938
What this trial is testing

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

Who this might be right for
Laryngeal CarcinomaHypopharyngeal Carcinoma
Fudan University 168
Testing effectiveness (Phase 2)Looking for participantsNCT05177133
What this trial is testing

Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)

Who this might be right for
Gastric AdenocarcinomaEsophageal Adenocarcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 25
Testing effectiveness (Phase 2)UnknownNCT05129189
What this trial is testing

Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression

Who this might be right for
HIV Infections
Shanghai Public Health Clinical Center 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT04462406
What this trial is testing

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Who this might be right for
Advanced MelanomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+8 more
ECOG-ACRIN Cancer Research Group 150
Testing effectiveness (Phase 2)Looking for participantsNCT06959108
What this trial is testing

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

Who this might be right for
Locally Advanced Head and Neck Squamous Cell Carcinoma
Groupe Oncologie Radiotherapie Tete et Cou 106
Testing effectiveness (Phase 2)UnknownNCT05023109
What this trial is testing

GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC

Who this might be right for
Biliary Tract Carcinoma
Shanghai Zhongshan Hospital 45
Early research (Phase 1)UnknownNCT03151447
What this trial is testing

Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Fudan University 18
Next Page